Evidence map›Paper›PMID 36854038›Full record

ArticlePloS one2023

HR LC-MS/MS metabolomic profiling of Yucca aloifolia fruit and the potential neuroprotective effect on rotenone-induced Parkinson's disease in rats.

Dalia E Ali, Samar M Bassam, Soha Elatrebi, Esraa S Habiba, Eman A Allam, Eman M Omar, Doaa A Ghareeb, Shaymaa A Abdulmalek, Essam Abdel-Sattar

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Therapeutic Potential ofInternational journal of molecular sciences · 2025
    Article
  5. Article
  6. Review
  7. Molecules (Basel, Switzerland) · 2025
    Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Dalia E AliPharmacognosy and Natural Products Department, Faculty of Pharmacy, Pharos University, Alexandria, Egypt.
Samar M BassamPharmacognosy and Natural Products Department, Faculty of Pharmacy, Pharos University, Alexandria, Egypt.
Soha ElatrebiClinical Pharmacology Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt.
Esraa S HabibaClinical Pharmacology Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt.
Eman A AllamMedical Physiology Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt.
Eman M OmarMedical Physiology Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt.
Doaa A GhareebBiochemistry Department, Faculty of Science, Alexandria University, Alexandria, Egypt.
Shaymaa A AbdulmalekBiochemistry Department, Faculty of Science, Alexandria University, Alexandria, Egypt.
Essam Abdel-SattarPharmacognosy Department, Faculty of Pharmacy, Cairo University, Giza, Egypt.ORCID 0000-0002-0617-1420
Alexandria University · EGPharos University in Alexandria · EGCairo University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Yucca aloifolia L. fruit (Yucca or Spanish bayonet, family Asparagaceae) is recognized for its purplish red color reflecting its anthocyanin content, which has a powerful antioxidant activity. This study aimed to investigate yucca (YA) fruit extract's protective effect on Parkinson's disease (PD). In vitro study, the anti-inflammatory activity of yucca fruit extracts was explored by measuring tumor necrosis factor receptor 2 (TNF-R2) and nuclear factor kappa B (NF-KB) to choose the most effective extract. Afterward, a detailed in vivo investigation of the protective effect of the most active extract on rotenone-induced PD was performed on male albino Wister rats. First, the safety of the extract in two different doses (50 and 100 mg/kg in 0.9% saline orally) was confirmed by a toxicological study. The rats were divided into four groups: 1) normal control (NC); 2) rotenone group; and third and fourth groups received 50 and 100 mg/kg yucca extract, respectively. The neurobehavioral and locomotor activities of the rats were tested by rotarod, open field, and forced swim tests. Striatal dopamine, renal and liver functions, and oxidative stress markers were assessed. Western blot analysis of brain tissue samples was performed for p-AMPK, Wnt3a, and β-catenin. Histopathological examination of striatal tissue samples was performed by light and electron microscopy (EM). The metabolites of the active extract were characterized using high-resolution LC-MS/MS, and the results showed the prevalence of anthocyanins, saponins, phenolics, and choline. Biochemical and histopathological tests revealed a dose-dependent improvement with oral Yucca extract. The current study suggests a possible neuroprotective effect of the acidified 50% ethanol extract (YA-C) of the edible Yucca fruit, making it a promising therapeutic target for PD.

Indexed as

Neuroprotective AgentsParkinson DiseaseYuccaAnimalsAnthocyaninsChromatography, LiquidFruitMalePlant ExtractsRatsRotenoneTandem Mass SpectrometryAnthocyaninsNeuroprotective AgentsPlant ExtractsRotenone

Identifiers

PMID36854038
PMCPMC9974117
OpenAlexW4322624624

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.